Orchestra BioMed Holdings, Inc. OBIO
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 31.98M | 32.72M | 33.48M | 2.82M | 2.94M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.98M | 32.72M | 33.48M | 2.82M | 2.94M |
| Cost of Revenue | 157.00K | 178.00K | 190.00K | 197.00K | 216.00K |
| Gross Profit | 31.82M | 32.55M | 33.29M | 2.62M | 2.73M |
| SG&A Expenses | 26.59M | 27.02M | 26.91M | 25.53M | 24.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 89.97M | 87.69M | 85.29M | 78.06M | 74.21M |
| Operating Income | -57.99M | -54.96M | -51.81M | -75.24M | -71.27M |
| Income Before Tax | -59.03M | -54.64M | -52.70M | -75.10M | -69.70M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -59.03 | -54.64 | -52.70 | -75.10 | -69.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -59.03M | -54.64M | -52.70M | -75.10M | -69.70M |
| EBIT | -57.99M | -54.96M | -51.81M | -75.24M | -71.27M |
| EBITDA | -57.64M | -54.63M | -51.48M | -74.91M | -70.94M |
| EPS Basic | -1.01 | -1.14 | -1.30 | -1.82 | -1.83 |
| Normalized Basic EPS | -0.65 | -0.73 | -0.81 | -1.14 | -1.14 |
| EPS Diluted | -1.01 | -1.14 | -1.30 | -1.82 | -1.83 |
| Normalized Diluted EPS | -0.65 | -0.73 | -0.81 | -1.14 | -1.14 |
| Average Basic Shares Outstanding | 240.69M | 215.27M | 190.78M | 166.88M | 152.31M |
| Average Diluted Shares Outstanding | 240.69M | 215.27M | 190.78M | 166.88M | 152.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |